PMID- 36272024
OWN - NLM
STAT- MEDLINE
DCOM- 20221103
LR  - 20230616
IS  - 1179-1950 (Electronic)
IS  - 0012-6667 (Print)
IS  - 0012-6667 (Linking)
VI  - 82
IP  - 14
DP  - 2022 Sep
TI  - Lenacapavir: First Approval.
PG  - 1499-1504
LID - 10.1007/s40265-022-01786-0 [doi]
AB  - Lenacapavir (Sunlenca((R))) is a long-acting capsid inhibitor of human 
      immunodeficiency virus type 1 (HIV-1) being developed by Gilead Sciences Inc. It 
      is available as an oral tablet and injectable solution, with the latter being a 
      slow-release formulation to allow bi-annual subcutaneous administration. In 
      August 2022, lenacapavir received its first approval in the EU for use in 
      combination with other antiretroviral(s) in adults with multi-drug resistant HIV 
      infection, for whom it is otherwise not possible to construct a suppressive 
      anti-viral regimen. This article summarizes the milestones in the development of 
      lenacapavir leading to this first approval for the treatment of HIV-1 infection.
CI  - (c) 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
FAU - Paik, Julia
AU  - Paik J
AD  - Springer Nature, Mairangi Bay, Private Bag 65901, Auckland, 0754, New Zealand. 
      dru@adis.com.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - New Zealand
TA  - Drugs
JT  - Drugs
JID - 7600076
RN  - 0 (Anti-HIV Agents)
RN  - 0 (Anti-Retroviral Agents)
SB  - IM
EIN - Drugs. 2023 Jul;83(11):1061. PMID: 37314634
MH  - Adult
MH  - Humans
MH  - *HIV Infections/drug therapy
MH  - *Anti-HIV Agents/pharmacology
MH  - *HIV-1
MH  - Anti-Retroviral Agents/therapeutic use
PMC - PMC10267266
COIS- During the peer review process the manufacturer of the agent under review was 
      offered an opportunity to comment on the article. Changes resulting from any 
      comments received were made by the authors on the basis of scientific 
      completeness and accuracy. Julia Paik is a salaried employee of Adis 
      International Ltd/Springer Nature, and declares no relevant conflicts of 
      interest. All authors contributed to the review and are responsible for the 
      article content.
EDAT- 2022/10/23 06:00
MHDA- 2022/11/04 06:00
PMCR- 2022/10/22
CRDT- 2022/10/22 11:18
PHST- 2022/10/23 06:00 [pubmed]
PHST- 2022/11/04 06:00 [medline]
PHST- 2022/10/22 11:18 [entrez]
PHST- 2022/10/22 00:00 [pmc-release]
AID - 10.1007/s40265-022-01786-0 [pii]
AID - 1786 [pii]
AID - 10.1007/s40265-022-01786-0 [doi]
PST - ppublish
SO  - Drugs. 2022 Sep;82(14):1499-1504. doi: 10.1007/s40265-022-01786-0.